Australasian Medical & Scientific

What Australasian Medical & Scientific does

Australasian Medical & Scientific Limited (trading as AMSL Diabetes) is the Australian and New Zealand exclusive distributor and commercial partner for Dexcom, Inc.'s continuous glucose monitoring (CGM) systems and for Tandem Diabetes Care's insulin pump products. Operating as a wholly-owned subsidiary of Dexcom, AMSL Diabetes distributes the Dexcom G7, Dexcom ONE+, and Dexcom G6 CGM systems, the t:slim X2 insulin pump with Control-IQ closed-loop automated insulin delivery technology, and supporting software platforms (Dexcom Clarity and Glooko) to patients with Type 1, Type 2, and gestational diabetes and to the healthcare professionals who manage them.

The company's revenue model is anchored on durable medical hardware plus recurring sensor/consumable reorders: CGM sensors are replaced approximately every 10-14 days and insulin pumps require ongoing infusion sets and accessories, generating high attach-rate annuity revenue on each installed patient base. Distribution is hybrid: direct-to-consumer e-commerce via shop.amsldiabetes.com.au, healthcare professional recommendations through a dedicated HCP portal and AMSL Education Hub, phone-based inside sales (1300 851 056), and importantly, participation in the Australian government subsidy program for subsidised Dexcom G7 access for Type 1 Diabetes patients. Marketing combines multi-channel digital presence, the 20,000+ member Dexcom Warriors community program, and live events across Australia. Operationally, the company is currently navigating two product-quality issues flagged on its homepage: a Product Alert for the t:slim X2 insulin pump and a Recall notice for the Dexcom G7 sensor.

Name

Australasian Medical & Scientific

Legal name

Australasian Medical and Scientific Limited

Website

https://amsl.com.au

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

101–250 employees

Short description

AMSL Diabetes is the exclusive Australian and New Zealand distributor of Dexcom continuous glucose monitoring systems and Tandem t:slim X2 insulin pumps with Control-IQ technology, serving patients with Type 1, Type 2, and gestational diabetes and the healthcare professionals who treat them, operating as a wholly-owned subsidiary of Dexcom, Inc.

Ownership category

akta.pro rank

Product category

Diabetes Management Medical Devices

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Type 1 Diabetes Care (HLAKADAB), Type 2 Diabetes Care (HLAKADAC), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)

Keywords

• Diabetes management devices
• Continuous glucose monitoring
• Insulin pump therapy
• Medical device distribution
• Blood glucose monitoring

Headquarters

HQ city

Chatswood

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. CGM Device and Sensor Sales: Sale of Dexcom continuous glucose monitoring devices and disposable sensors to patients with diabetes. Sensors require regular replacement (typically every 10-14 days for G7).
2. Insulin Pump Sales: Sale of Tandem t:slim X2 insulin pumps to patients requiring insulin therapy. Pumps are durable medical equipment with ongoing sensor and accessory purchases.
3. Diabetes Accessories and Consumables: Sale of accessories including HypoPak Fast Acting Glucose, infusion sets, and other diabetes management supplies through the online shop.
4. Subsidized CGM Program: Australians living with Type 1 Diabetes can access subsidised Dexcom G7 through government subsidy programs, suggesting participation in reimbursement schemes.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Australasian Medical & Scientific (AMSL Diabetes) distributes and supplies diabetes management technologies in Australia and New Zealand, including the t:slim X2 insulin pump with Control-IQ technology, Dexcom continuous glucose monitoring (CGM) systems (G7, G6, ONE+), and supporting diabetes data and accessory products. The company operates as a specialized distributor serving people with Type 1 and Type 2 diabetes as well as the healthcare professionals who support them.

Product overview

Australasian Medical & Scientific (AMSL Diabetes) operates as a Dexcom company distributing a portfolio of diabetes management products. The core offering consists of the t:slim X2 Insulin Pump with Control-IQ Technology (Tandem Diabetes Care) and the Dexcom Continuous Glucose Monitoring portfolio including G7, G6, and ONE+ models. The Control-IQ system integrates with Dexcom CGM to provide automated insulin delivery. Supporting products include Dexcom Clarity and Glooko for data management, and HypoPak for hypoglycemia treatment. The company also supports the Dexcom Warrior community program.

Differentiator

Problem solved

Functional benefit

Products and services

• Dexcom G7 Continuous Glucose Monitoring System A wearable continuous glucose monitor that provides real-time interstitial glucose readings for people with diabetes, intended for adults and children with Type 1 or Type 2 diabetes who need ongoing glucose visibility to support insulin dosing and lifestyle decisions.
• Dexcom G6 Continuous Glucose Monitoring System A continuous glucose monitoring system that streams glucose data to a smartphone or receiver, designed for people with diabetes who require regular glucose trend data to manage insulin therapy.
• Dexcom ONE+ Continuous Glucose Monitoring System A simplified Dexcom CGM offering aimed at people with Type 2 diabetes who are new to continuous glucose monitoring and want accessible, smartphone-connected glucose data.
• t:slim X2 Insulin Pump with Control-IQ Technology An insulin pump that uses Control-IQ automated insulin delivery algorithms, integrating with a CGM to adjust insulin delivery for people with Type 1 diabetes who want hybrid closed-loop therapy.
• Dexcom Clarity A cloud-based diabetes data management and reporting platform that analyses CGM data to produce trend reports, time-in-range metrics, and pattern insights for patients and their healthcare professionals.
• Glooko A diabetes data aggregation platform that allows people with diabetes to consolidate data from multiple glucose meters, insulin pumps, and CGMs and share reports with their care team.
• HypoPak An emergency hypoglycaemia treatment kit for people with diabetes who experience severe low blood glucose events and require rapid glucose or glucagon intervention.

Quantifiable outcome

• Zero fingerpricks required for glucose monitoring
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• DexcomcoreOEM/ Whitelabel/ Licensing PartnerAustralasian Medical and Scientific Limited is a Dexcom company, serving as the exclusive distributor and commercial partner for Dexcom CGM products in Australia and New Zealand. AMSL Diabetes markets and distributes Dexcom G7, Dexcom ONE+, and Dexcom G6 CGM systems along with related software platforms including Dexcom Clarity.
• Tandem Diabetes CarecoreTechnology or IntegrationAMSL Diabetes distributes Tandem Diabetes Care products including the t:slim X2 insulin pump with Control-IQ technology in Australia and New Zealand. The integration between Tandem insulin pumps and Dexcom CGM systems enables automated insulin delivery based on real-time glucose data.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Roche Diabetes Care: Incumbent diabetes player offering Accu-Chek blood glucose meters and growing CGM offerings. Sells into the same Australian HCPs and patients as AMSL across a broader portfolio.
• LifeScan (Platinum Equity): OneTouch blood glucose monitoring brand with legacy reach into Australian diabetes care. Adjacent incumbent whose meter business is being pressured by the CGM shift that AMSL leads.

Direct peers

• Abbott Diabetes Care: Markets the FreeStyle Libre CGM family and competes head-to-head with Dexcom in Australia across both Type 1 and Type 2 diabetes segments. Directly comparable CGM product set and target HCPs/patients.
• Medtronic Diabetes: Sells integrated insulin pumps (e.g., MiniMed series) with its own CGM and closed-loop algorithms. Competes with AMSL's Tandem Control-IQ + Dexcom G7 closed-loop offering in Australia and globally.
• Insulet Corporation: Manufactures the Omnipod patch pump, a competing wearable insulin delivery platform with CGM integration. Targets the same insulin-requiring diabetes patients as AMSL's Tandem t:slim offering.
• Ypsomed: Swiss maker of the mylife Loop insulin pump system that integrates with third-party CGMs. Competes in the same AID category as Tandem's Control-IQ distributed by AMSL.

Emerging players

• Ascensia Diabetes Care: Sells Contour blood glucose meters and is investing in digital diabetes management; serves the same patient population in Australia where AMSL is pushing CGM adoption.

Regional players

• A. Menarini Diagnostics: Distributes CGM and BGM products across Europe and other regions; comparable regional diabetes medical-device distributor model to AMSL's ANZ franchise.
• EBOS Group: Largest Australasian medical device and pharmaceutical distributor (including Symbion). Operates adjacent wholesale channels for diabetes and chronic-care products that compete or partner with AMSL in ANZ.

Others

• Glooko: Diabetes data management platform already integrated into AMSL's offering; functions as an enabling/ecosystem participant rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australasian Medical & Scientific